表皮生长因子受体靶向治疗在非小细胞肺癌的进展
摘要
肺癌是恶性肿瘤中高发病率、主要致死性疾病.NSCLC占肺癌总数80%,大部分患者初诊即为晚期,许多早期患者手术根治后仍出现复发、转移,临床缓解和提高患者生存质量仍是主要治疗目标.
……
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2005年第z2期714-716,共3页
Chinese Journal of Modern Applied Pharmacy
参考文献18
-
1[1]Ciardiello F, Giampaolo T. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 2001;7(10):2958-2970.
-
2[2]Tien H, Anne MT, Joan HS. Novel therapies for lung cancer. Surg Oncol,2002;11 (4) 229-241.
-
3[3]Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomizedphase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Clin Oncol, 2003;21(12):2237-2246.
-
4[4]Kris MG, Natale BR, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer a randomized trial. JAMA, 2003;290(16):2149 2158.
-
5[5]Copin M, Kommareddy A, Behnken D, et al. Gefitinib in elderly patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 2003;(22):758-761.
-
6[6]Gridelli C, Maione P, Castaldo V,et al. Gefitinib in elderly and unfit patients affected by advanced non-small cell lung cancer. Br J Cancer, 2003;(89):1827 1829.
-
7[7]Cappuzzo F, Bartolini S, Ceresoli GL, et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer, 2004;(90):82 86.
-
8[8]Giaccone G, Johnson DH, Manegold C, et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-smallcell lung cancer (INTACT 1) . Ann Oncol,2002;(13):2-6.
-
9[9]Johnson DH, Herbst R, Giaccone G, et al. ZD1839 (Iressa) in combination with paclitaxel, ZD1839 (Iressa) in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): results from a phaseIII clinical trial (INTACT 2) . Ann Oncol, 2002;(13):127-132.
-
10[10]Fandi A, Gatzemeier U, Smith R, Averbuch S, Manegold C. Final data from a pilot trial of gefitinib (ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): safety and pharmacokinetics. Proc Am Soc Clin Oncol, 2003;(22):655-663.
-
1肖志,石欣.影响胰腺癌病人预后的因素研究进展[J].实用肿瘤学杂志,2008,22(2):173-177. 被引量：6
-
2黄炜燊,杨力.预测慢性乙型肝炎患者肝癌发生的评分系统[J].临床肝胆病杂志,2011,27(4):363-364. 被引量：3
-
3易小芳,邢荣春,郑家芬.微小RNA-200家族与肿瘤关系的研究进展[J].中国全科医学,2013,16(11):1309-1312. 被引量：4
-
4夏咸军,张丽军,刘保池.结肠癌蛋白质组学研究进展[J].国际外科学杂志,2011,38(12):839-842. 被引量：2
-
5李宏军,王苏丹,张琦.肝癌磁共振分子影像早期诊断的研究进展[J].北京医学,2016,38(12):1261-1263. 被引量：4
-
6于丽.2008年肿瘤新药点评[J].中国处方药,2009,8(2):60-63.
-
7倪艳秋.艾迪注射液联合化疗治疗复治恶性肿瘤的临床观察[J].丹东医药,2007,0(2):12-13.
-
8涂康生,姚英民.肝细胞癌中上皮间质转化及其相关信号通路的研究进展[J].世界华人消化杂志,2016,24(14):2131-2142. 被引量：1
-
9黄宝星,孙福康.前列腺癌环氧合酶-2表达的分子机制研究进展[J].中华泌尿外科杂志,2013,34(5):397-400. 被引量：3
-
10于淑清.肺结核治疗的临床进展[J].国外医学情报,2005,26(10):10-14.
